RICHMOND, Calif., Jan. 5 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 2:00 pm (PT) on Monday, January 12, 2009 at the J.P. Morgan Healthcare Conference in San Francisco.
The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.
Sangamo BioSciences, Inc. is focused on the research and development of
novel DNA-binding proteins for therapeutic gene regulation and modification.
The most advanced ZFP Therapeutic(TM) development program is currently in
Phase 2 clinical trials for evaluation of safety and clinical effect in
patients with diabetic neuropathy and amyotrophic lateral sclerosis (ALS).
Other therapeutic development programs are focused on HIV/AIDS, cancer,
neuropathic pain, nerve regeneration, Parkinson's disease and monogenic
diseases. Sangamo's core competencies enable the engineering of a class of
DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By
engineering ZFPs that recognize a specific DNA sequence Sangamo has created
ZFP transcription factors (ZFP TF(TM)) that can control gene expression and,
consequently, cell function. Sangamo is also developing sequence-specific ZFP
Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic
partnerships with companies in non-therapeutic areas including Dow
|SOURCE Sangamo BioSciences, Inc.|
Copyright©2009 PR Newswire.
All rights reserved